According to The Australian Financial Review, Melbourne-based biotech company Firebrick Pharma has developed a "disinfectant for your nose" that could be capable of reducing the amount of detectable coronavirus by almost 100 per cent.
In a report seen by The Australian Financial Review, laboratory tests in a test tube showed its nasal spray, Nasodine, reduced the amount of detectable coronavirus by 99.97 per cent and eliminated the infectious properties of any remaining virus.
The company, founded in 2012 by Betadine throat gargle creator Dr Peter Molloy, tested its nasal spray on the coronavirus on the basis that it kills viruses indiscriminately, so logically could be effective on the coronavirus – as well as SARS, MERS or influenza.
The catch is that the patented nasal spray, developed to-date as a combative measure against the common cold, is in the final stages of its phase three clinical trial and yet to be approved for use by any global regulators.
Dr Molloy is hoping to receive permission from the health department and the Therapeutic Goods Administration to make the nasal spray available in special conditions to healthcare workers at risk of exposure to the coronavirus.
If you want to read this article in Japanese, please see the following link:
Subscribe to our English Newsletter